← Back to Search

Behavioural Intervention

Decision Support Tool for Lung Cancer Screening

N/A
Waitlist Available
Led By Kensaku Kawamoto, MD, PhD, MHS
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Does not already have lung cancer
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 18 months for the intervention period and 12 months for the baseline period
Awards & highlights

Study Summary

This trial is designed to increase the use of low-dose CT scans to screen for lung cancer by developing and disseminating patient-centered clinical decision support tools. These tools will be integrated with electronic health records and clinical workflows, and will prompt shared decision making when patients meet screening criteria. The goal is to promote standard of care that is endorsed by the Centers for Medicare & Medicaid Services and the US Preventive Services Task Force.

Who is the study for?
This trial is for people aged 55 to 80 who are patients at University of Utah primary care clinics, have a history of heavy smoking (30+ pack-years), and are either current smokers or quit within the last 15 years. It's not for those already diagnosed with lung cancer.Check my eligibility
What is being tested?
The study tests a new tool that helps doctors and patients decide together if lung cancer screening is right. The tool works with electronic health records, prompts shared decision-making when criteria are met, and provides personalized info on screening pros and cons.See study design
What are the potential side effects?
Since this trial involves decision support tools rather than medications or medical procedures, traditional side effects aren't expected. However, there may be psychological impacts from discussing potential benefits and harms of lung cancer screening.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have lung cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 18 months for the intervention period and 12 months for the baseline period
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 18 months for the intervention period and 12 months for the baseline period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in LDCT screening rate among eligible patients
Secondary outcome measures
Estimated number of lung cancer deaths prevented
Estimated number of major complications
Other outcome measures
Rate of use of the intervention
Return on investment
Usability of the intervention as measured by System Usability Scale

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients eligible for LDCT lung cancer screeningExperimental Treatment1 Intervention
This population will consist of patients eligible for, or potentially eligible for, LDCT lung cancer screening according to USPSTF guidelines, who are seen by a pilot user of the intervention. The inclusion criteria are (i) >= 55 years and <= 80 years old at the time of the visit; (ii) does not already have lung cancer; and (iii) meets USPSTF smoking criteria for LDCT screening (30+ pack-year smoking history and current smoker or quit in the past 15 years) or may meet the criteria if a complete smoking history were taken. USPSTF guidelines may change during the study. In particular, it is anticipated that the guidelines may update during the study whereby the minimum age is reduced to 50 (from 55) and the minimum smoking history is reduced to 20 years (from 30). In the event that the USPSTF guidelines change, the intervention will be updated to match the change to the guidelines. We may also update the study evaluation to match the updated USPSTF guidelines.

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,095 Previous Clinical Trials
1,763,585 Total Patients Enrolled
Kensaku Kawamoto, MD, PhD, MHSPrincipal Investigator - University of Utah
University of Utah
1 Previous Clinical Trials
13,155 Total Patients Enrolled

Media Library

EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04498052 — N/A
Lung Cancer Research Study Groups: Patients eligible for LDCT lung cancer screening
Lung Cancer Clinical Trial 2023: EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening Highlights & Side Effects. Trial Name: NCT04498052 — N/A
EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04498052 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are eligible to join this clinical experiment?

"Yes, the information from clinicaltrials.gov supports that this medical trial is actively recruiting volunteers. First posted on August 23rd 2020 and last updated May 24th 2022, it seeks to enroll 12000 individuals at a single location."

Answered by AI

Are there still available slots for individuals to participate in this clinical trial?

"All signs point to this trial actively seeking recruits; the original posting date was August 23rd 2020, with recent changes made on May 24th 2022."

Answered by AI

Is this investigation accepting individuals who are sixty or more years of age?

"This study necessitates that candidates are between the ages of 55 and 80. Furthermore, there are 37 trials available for patients below 18 years old, while 1500 clinical studies cater to those above 65."

Answered by AI

Is enrollment in this clinical trial still open to new participants?

"This extensive clinical trial aims to recruit 12,000 patients suffering from lung cancer between the ages of 55 and 80. Those wishing to enrol must meet certain criteria such as obtaining care at University of Utah primary care clinics; not having previously contracted lung cancer; meeting United States Preventive Services Task Force (USPSTF) criteria for Low Dose Computed Tomography (LDCT) screening. This includes being aged 55 or above and no more than eighty years old, possessing a smoking history of 30+ pack-years as well as either still being a smoker or having quit in the last fifteen years."

Answered by AI
Recent research and studies
New England Journal of MedicineJournal
Selection Criteria for Lung-cancer Screening
Tammemägi, Martin C., Hormuzd A. Katki, William G. Hocking, Timothy R. Church, Neil Caporaso, Paul A. Kvale, Anil K. Chaturvedi, et al.. 2013. “Selection Criteria for Lung-cancer Screening”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1211776.
clinicaltrials.govStudy
Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening
Kensaku Kawamoto, MD, PhD, MHS 2020. "Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04498052.
All > Metastatic Lung Cancer > Lung Cancer
~2571 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top